Taking Aim at Non-Small Cell Lung Cancer: The Emerging Role of Molecular Biomarkers and Tumor Histology for Optimal Treatment Selection

This high-energy program will provide in-depth interaction and collaboration between the participants and expert faculty. The program will begin with a didactic keynote presentation and transition into several highly interpersonal and interactive breakout sessions, where participants will work together to extensively analyze several case study scenarios in collaboration with an expert faculty facilitator.

The outcomes of the case study discussions will be presented, and the expert faculty will rank each study group's findings. The group garnering the highest score will be awarded the "Oncology Masters Certificate" during the closing awards ceremony.

Due to the program structure and format, space is limited and preregistration is required.

Program Agenda

8:00 am-8:30 am	Registration/Breakfast
8:30 am-8:40 am	Introductions and Expectations
8:40 am-9:20 am	Keynote Address: Taking Aim at Non-Small Cell Lung Cancer: The Emerging Role of Molecular Biomarkers and Tumor Histology for Optimal Treatment Selection
9:20 am-9:30 am	Break
9:30 am-10:45 am	Concurrent Sessions-Small-Group Interactive Case Study Sessions
10:45 am-11:05 am	Refreshment Break (Faculty Rating of Case Study Sessions)
11:05 am-11:45 am	Keynote Wrap-Up and Case Summations
11:45 am-11:55 am	Oncology Masters Reveal and Certificate Awards Ceremony
11:55 am-12:00 pm	Closing Remarks and Program Evaluation

Program Overview
Despite extensive research and years of intense investigation, lung cancer remains an extremely elusive disease. Treatments for lung cancer appear to have reached an efficacy plateau and, as a result, lung cancer remains the leading cause of cancer-related death. Recent clinical data have demonstrated that non-small cell lung cancer (NSCLC) is a very heterogeneous disease. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Oncology healthcare providers (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients.

Using a highly interactive and engaging format, participants will be provided with up-to-date information on current and emerging therapeutic approaches to managing the care of patients with advanced NSCLC.

Intended Audience
This activity is intended for medical and surgical oncologists, radiation oncologists, thoracic surgeons, pathologists, pulmonologists, oncology nurses, and other HCPs interested in the care of patients with NSCLC.

Learning Objectives
At the conclusion of this activity, participants should be able to:

• Outline the limitations of the current chemotherapeutic armamentarium for advanced NSCLC
• Describe the rationale for inhibition of signaling pathways as a therapeutic strategy for patients with advanced NSCLC
• Identify key patient characteristics that may preclude NSCLC patients from receiving various novel targeted agents
• Explain the emerging interest in histological subtypes and molecular biomarkers for guiding appropriate treatment selection in patients with advanced NSCLC

CME/CE Accreditation and Statements
Physicians
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IMNE designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Committee on Accreditation.

IMNE designates this educational activity for 3.0 contact hours (0.3 CEUs). Accreditation by the ANCC's Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Commercial Support Acknowledgment
This activity is supported by an educational grant from Lilly USA, LLC.

Americans with Disabilities Act Compliance
IMNE is fully compliant with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If you are in need of accommodations, please contact Katie Fidanza at katie.fidanza@imne.com or via phone at +1 404 443 1511.